Ocugen, Inc. (OCGN): Operating Income
-$62.92M
Year ended 2025-12-31
-$68.90M
Trailing 12 months to 2026-06-30
| Period ended | Operating Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$62.92M | n/m | 2026-03-04, From 2025-01-01 |
| 2024-12-31 | -$54.76M | n/m | 2026-03-04, From 2024-01-01 |
| 2023-12-31 | -$65.53M | n/m | 2025-03-05, From 2023-01-01 |
| 2022-12-31 | -$89.07M | n/c | 2024-04-16, From 2022-01-01 |
| 2021-12-31 | -$58.03M | n/m | 2023-02-28, From 2021-01-01 |
| 2020-12-31 | -$21.29M | n/m | 2022-02-28, From 2020-01-01 |
| 2019-12-31 | -$14.16M | n/m | 2022-02-28, From 2019-01-01 |
| 2018-12-31 | -$16.14M | n/c | 2020-03-27, From 2018-01-01 |
| 2017-12-31 | -$24.95M | n/m | 2019-03-22, From 2017-01-01 |
| 2016-12-31 | -$30.31M | n/m | 2018-03-15, From 2016-01-01 |
| 2015-12-31 | -$31.82M | n/m | 2017-03-16, From 2015-01-01 |
| 2014-12-31 | -$32.66M | n/a | 2016-03-10, From 2014-01-01 |
Operating Income at similar companies
| Company | Year ended | Operating Income | Change YoY |
|---|---|---|---|
| Ocugen, Inc. (OCGN) | 2025-12-31 | -$62.92M | n/m |
| Prime Medicine, Inc. (PRME) | 2025-12-31 | -$208.35M | n/m |
| CG Oncology, Inc. (CGON) | 2025-12-31 | -$190.77M | n/m |
| Zeo ScientifiX, Inc. (ZEOX) | 2025-10-31 | -$5.39M | n/m |
| CRISPR Therapeutics AG (CRSP) | 2025-12-31 | -$664.57M | n/m |
| Surrozen, Inc. (SRZN) | 2025-12-31 | -$42.09M | n/m |
| DBV Technologies S.A. (DBVT) | 2025-12-31 | -$147.06M | n/m |
| Dyadic International Inc (DYAI) | 2025-12-31 | -$7.19M | n/m |
| Fate Therapeutics Inc (FATE) | 2025-12-31 | -$147.70M | n/m |
Compare OCGN, PRME, CGON, ZEOX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗